This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
== Clinical significance == Proenkephalin is produced by the medium spiny neurons of the striatum which undergo neurodegeneration in early stages of Huntington's disease (HD). PENK and related peptides measured in cerebrospinal fluid are proposed as potential biomarkers of disease progression in HD. Furthermore, PENK has been found associated with acute kidney injury and glomerular filtration rate in steady-state and critically ill patients.
== Popular culture == The 1977 movie Clark, had Olofsson as co-writer on the script. Folkhemsdesperadon (2001) is a documentary with an interview with Olofsson. Norrmalmstorgsdramat inifrån (2003) is an interview with the bank-robber Jan-Erik Olsson, who demanded that Olofsson be allowed to come to the bank. In the film Norrmalmstorg (2003), Olofsson is portrayed by Shanti Roney. The podcast Criminal spoke with Olofsson about the Norrmalmstorg robbery in their episode "Hostage." In January 2020, Sveriges Television aired the documentary Clark - en rövarhistoria. The documentary was criticized for portraying Olofsson like an idol, and because it had been produced by Alexander Eriksson, one of the convicted robbers from the Västberga helicopter robbery. On 11 May 2020, Netflix announced Clark, a limited six-episode drama series about Clark Olofsson. The series, directed by Jonas Åkerlund, aired in May 2022. Olofsson is played by Bill Skarsgård.
=== Space science and planetary research === Space science and planetary research at the University of Arizona are largely conducted through the Lunar and Planetary Laboratory (LPL), which has led or contributed to numerous NASA missions. The university received more than $325 million for the LPL to lead NASA's 2007–08 Phoenix Mars Mission, which explored the Martian Arctic. It later received another $800 million for the OSIRIS-REx mission, the first mission in U.S. history to collect a sample from an asteroid. The LPL's contributions to the Cassini mission orbiting Saturn were larger than those of any other university in the world. University researchers designed and operated the spacecraft's atmospheric radiation and imaging investigations. The university also operates the HiRISE camera aboard the Mars Reconnaissance Orbiter. The spacecraft reached Mars in March 2006 after traveling 300 million miles. The University of Arizona-designed camera was led by planetary scientist Alfred McEwen, the project's principal investigator. HiRISE captured high-resolution images of the planet. In 2011, University of Arizona alumnus and planetary scientist Lujendra Ojha and his research team used HiRISE imagery to identify evidence of liquid water on the surface of Mars. NASA confirmed the discovery in 2015. The university receives more NASA grants annually than the next nine top NASA-Jet Propulsion Laboratory-funded universities combined. In August 2007, the University of Arizona, under the direction of planetary scientist Peter Smith, led the Phoenix Mars Mission.
Sources: en.wikipedia.org
Monosynaptic reflex A reflex arc that involves only one synapse between a sensory neuron and a motor neuron, such as the knee-jerk (patellar) reflex. Mossy fiber A type of excitatory input fiber to the cerebellum originating from the spinal cord and brainstem nuclei. They synapse onto granule cells. Motor cortex A region of the frontal lobe involved in planning, controlling, and executing voluntary movements. Motor neuron A type of neuron that transmits signals from the central nervous system to muscles or glands, enabling movement and action. Motor unit A motor neuron and all the muscle fibers it innervates. Varies in size depending on the precision required by the muscle. MRI spectroscopy A specialized MRI technique that measures concentrations of certain brain chemicals or metabolites, aiding in diagnosis of tumors and metabolic disorders. Multisensory integration The process by which the brain combines information from different sensory modalities (e.g., vision and sound) to create coherent perception. Myelin A fatty substance that insulates axons, increasing the speed and efficiency of action potential conduction. Formed by oligodendrocytes in the CNS and Schwann cells in the PNS. Myelination The process of forming a myelin sheath around axons, critical for normal neural function. Occurs progressively during development. Myoclonus Sudden, involuntary muscle jerks or twitches. Can be physiological (e.g., sleep starts) or associated with neurological disorders.
Cochran (born 1929), American chemist, known for pioneering studies on the nature of free radicals Ernst Cohen (1869–1944 Auschwitz), Dutch chemist known for work on the allotropy of metals) Mildred Cohn (1913–2009), American chemist, a pioneer in the applying nuclear magnetic resonance to enzyme reactions, particularly reactions of adenosine triphosphate David Collison (PhD 1980), British chemist known for development of electron paramagnetic resonance spectroscopy Vicki Colvin (born 1965), American chemist known for work on the synthesis and characterization of nanomaterials James Bryant Conant (1893–1978), American organic chemist who explored the complex relationship between chemical equilibrium and the reaction rate of chemical processes, Priestley Medal 1944 Elias James Corey (born 1928), American organic chemist, winner of the 1990 Nobel Prize in Chemistry for developing the theory and methodology of organic synthesis, specifically retrosynthetic analysis Robert Corey (1897–1971), American biochemist known for co-discovery of the α-helix and the β-sheet Carl Ferdinand Cori (1896–1984), Czech biochemist, Nobel Prize in physiology or medicine 1947 for discovering how glycogen is broken down and resynthesized Gerty Cori (1896–1957), American biochemist, Nobel Prize in physiology or medicine 1947 for discovering how glycogen is broken down and resynthesized John Cornforth (1917–2013), Australian-British chemist, 1975 Nobel Prize in Chemistry for work on the stereochemistry of enzyme-catalysed reactions Athel Cornish-Bowden (born 1943).
The gastrointestinal wall of the gastrointestinal tract is made up of four layers of specialised tissue. From the inner cavity of the gut (the lumen) outwards, these are the mucosa, the submucosa, the muscular layer and the serosa or adventitia. The mucosa is the innermost layer of the gastrointestinal tract. It surrounds the lumen of the tract and comes into direct contact with digested food (chyme). The mucosa itself is made up of three layers: the epithelium, where most digestive, absorptive and secretory processes occur; the lamina propria, a layer of connective tissue, and the muscularis mucosae, a thin layer of smooth muscle. The submucosa contains nerves including the submucous plexus (also called Meissner's plexus), blood vessels and elastic fibres with collagen, that stretches with increased capacity but maintains the shape of the intestine. The muscular layer surrounds the submucosa. It comprises layers of smooth muscle in longitudinal and circular orientation that also helps with continued bowel movements (peristalsis) and the movement of digested material out of and along the gut. In between the two layers of muscle lies the myenteric plexus (also called plexus). The serosa/adventitia are the final layers. These are made up of loose connective tissue and coated in mucus so as to prevent any friction damage from the intestine rubbing against other tissue. The serosa is present if the tissue is within the peritoneum, and the adventitia if the tissue is retroperitoneal.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.